Skip to content

Study · Case report or series · n = 3 · 1991

4 results

Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance.

Schoenle EJ, Zenobi PD, Torresani T, Werder EA, Zachmann M, Froesch ER

Diabetologia1 Sept 1991Cited by 72 (Europe PMC)

PMID1955101 (opens in a new tab)DOI10.1007/bf00400998 (opens in a new tab)PepBankPUB-01955101
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    IGF-I produced an immediate but slow fall in blood glucose in women with type A insulin resistance.

    In plain wordsIGF-I reduced blood sugar slowly in women with type A insulin resistance.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseBlood glucose
    Study

    n = 3

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    two subsequent doses of 100 micrograms/kg body weight · intravenousAs given in this study (human).

    Source sentences

    Summary
    An immediate but slow fall of blood glucose was observed.
    1 context sentence
    Summary · context
    Recombinant human insulin-like growth factor I was intravenously administered in two subsequent doses of 100 micrograms/kg body weight to three women with type A insulin resistance.
  2. 02HumanCase report or seriesEfficacy outcome

    After IGF-I in women with type A insulin resistance, the glucose disappearance rate was 28.0 mumol/min, which the authors describe as considerably lower than in healthy subjects.

    In plain wordsAfter IGF-I, women with type A insulin resistance had a glucose disappearance rate of 28.0 mumol/min, which the authors call lower than in healthy people.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    Not applicableGlucose disappearance rate
    Study

    n = 3

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    two subsequent doses of 100 micrograms/kg body weight · intravenousAs given in this study (human).

    Measurements

    Glucose disappearance rate
    28 mumol/min
    women with type A insulin resistance after IGF-I

    Source sentences

    Summary
    The glucose disappearance rate was 28.0 mumol/min, i.e. considerably lower than that seen in healthy subjects.
    1 context sentence
    Summary · context
    Recombinant human insulin-like growth factor I was intravenously administered in two subsequent doses of 100 micrograms/kg body weight to three women with type A insulin resistance.
  3. 03HumanCase report or seriesEfficacy outcome

    IGF-I reduced elevated insulin levels in women with type A insulin resistance, but levels did not normalize.

    In plain wordsIGF-I reduced insulin in women with type A insulin resistance, but levels remained above normal.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseInsulin levels
    Study

    n = 3

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    two subsequent doses of 100 micrograms/kg body weight · intravenousAs given in this study (human).

    Source sentences

    Summary
    The markedly elevated insulin and C-peptide levels fell in a parallel manner to blood glucose but not to normal levels.
    1 context sentence
    Summary · context
    Recombinant human insulin-like growth factor I was intravenously administered in two subsequent doses of 100 micrograms/kg body weight to three women with type A insulin resistance.
  4. 04HumanCase report or seriesEfficacy outcome

    IGF-I reduced elevated C-peptide in women with type A insulin resistance, but levels did not normalize.

    In plain wordsIGF-I reduced C-peptide in women with type A insulin resistance, but levels remained above normal.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseC-peptide levels
    Study

    n = 3

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    two subsequent doses of 100 micrograms/kg body weight · intravenousAs given in this study (human).

    Source sentences

    Summary
    The markedly elevated insulin and C-peptide levels fell in a parallel manner to blood glucose but not to normal levels.
    1 context sentence
    Summary · context
    Recombinant human insulin-like growth factor I was intravenously administered in two subsequent doses of 100 micrograms/kg body weight to three women with type A insulin resistance.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.